The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?

The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?

Bibliographic Details
Main Authors:	Amy L. Cummings, Edward B. Garon
Format:	Article
Language:	English
Published:	China Anti-Cancer Association 2017-08-01
Series:	Cancer Biology & Medicine
Subjects:	Immunotherapy immune checkpoint inhibitors biomarkers first-line treatment
Online Access:	http://www.cancerbiomed.org/index.php/cocr/article/view/1069

Similar Items

Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity
by: Barbara Seliger
Published: (2019-05-01)

Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors
by: Magdalena Olbryt, et al.
Published: (2020-06-01)

Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors
by: Ho Jung An, et al.
Published: (2021-08-01)

Predictive biomarkers for tumor immune checkpoint blockade
by: Tong M, et al.
Published: (2018-10-01)

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
by: Pan Shen, et al.
Published: (2021-07-01)

Progress of Steroids Effect on Efficacy of Immune Checkpoint Inhibitors
by: Guoqiang PAN, et al.
Published: (2019-12-01)

Predictive biomarkers of response to immune checkpoint inhibitors
by: María Sacramento Díaz-Carrasco, et al.
Published: (2020-07-01)

The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients
by: Katarzyna Tomela, et al.
Published: (2020-09-01)

Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy
by: Sven H. Loosen, et al.
Published: (2021-04-01)

Blood-based Biomarkers in the Immune Checkpoint Inhibitor Treatment in  Non-small Cell Lung Cancer
by: Peng WANG, et al.
Published: (2021-07-01)

Research Progress of Immune Checkpoint Inhibitors  in Malignant Pleural Mesothelioma
by: Yaru HUANG, et al.
Published: (2021-06-01)

Calcineurin inhibitors in steroid and anti‐TNF‐alpha refractory immune checkpoint inhibitor colitis
by: Eva Zhang, et al.
Published: (2021-05-01)

Clinical Diagnosis and Treatment Recommendations for the Pneumonitis Associated with Immune Checkpoint Inhibitor
by: Hanping WANG, et al.
Published: (2019-10-01)

Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice
by: Hui-Ching Wang, et al.
Published: (2020-10-01)

Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry
by: Aasems Jacob, et al.
Published: (2021-03-01)

Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma
by: Stephanie Sanders, et al.
Published: (2020-04-01)

Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer
by: Boris Duchemann, et al.
Published: (2020-12-01)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
by: Hanping Wang, et al.
Published: (2020-01-01)

Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC
by: Jialin Qu, et al.
Published: (2020-07-01)

Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives
by: Fulvio Borella, et al.
Published: (2020-03-01)

The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma
by: Nicholas Meti, et al.
Published: (2018-06-01)

Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
by: Anne Dyhl-Polk, et al.
Published: (2021-06-01)

Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
by: H. Taghizadeh, et al.
Published: (2019-11-01)

Current Progress and Future Perspectives of Immune Checkpoint Inhibitors in Biliary Tract Cancer
by: Seesaha PK, et al.
Published: (2021-03-01)

Immune checkpoint inhibitor associated ocular hypertension (from presumed trabeculitis)
by: Julia Canestraro, et al.
Published: (2021-09-01)

Immune checkpoint inhibitors in the treatment of virus-associated cancers
by: Peipei Gao, et al.
Published: (2019-06-01)

Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic
by: Alex Friedlaender, et al.
Published: (2020-05-01)

Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors
by: François Bertucci, et al.
Published: (2021-01-01)

Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy
by: Hiromichi Nakajima, et al.
Published: (2021-01-01)

Response to Immune Checkpoint Inhibitor Treatment in Advanced Cervical Cancer and Biomarker Study
by: Kevin R. Shieh, et al.
Published: (2021-08-01)

Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors
by: Noelia Vilariño, et al.
Published: (2020-08-01)

Advance in Drug Resistance Mechanism of Immune Checkpoint Inhibitors
by: ZHANG Lanlan, et al.
Published: (2020-08-01)

Research Progress of Intestinal Microbiota and Immune Checkpoint Inhibitors
by: DAN Huimin, et al.
Published: (2019-11-01)

Management of Dermatologic Toxicities Related to Immune Checkpoint Inhibitors
by: Xiaoyan SI, et al.
Published: (2019-10-01)

First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress
by: Zhangfeng Huang, et al.
Published: (2020-10-01)

Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review
by: Tae Jin Kim, et al.
Published: (2020-07-01)

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors in the Management of Brain Metastases
by: Eric J. Lehrer, et al.
Published: (2018-10-01)

Premature clinical trial discontinuation in the era of immune checkpoint inhibitors
by: Khunger, Monica, et al.
Published: (2018)

Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience
by: Omar Mamlouk, et al.
Published: (2019-01-01)

Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors
by: Konstantinos Melissaropoulos, et al.
Published: (2020-05-01)